MX2022005404A - Compuestos de fijación a il-2r e il-7r dual. - Google Patents

Compuestos de fijación a il-2r e il-7r dual.

Info

Publication number
MX2022005404A
MX2022005404A MX2022005404A MX2022005404A MX2022005404A MX 2022005404 A MX2022005404 A MX 2022005404A MX 2022005404 A MX2022005404 A MX 2022005404A MX 2022005404 A MX2022005404 A MX 2022005404A MX 2022005404 A MX2022005404 A MX 2022005404A
Authority
MX
Mexico
Prior art keywords
binding compounds
dual
receptor binding
dual receptor
diseases
Prior art date
Application number
MX2022005404A
Other languages
English (en)
Spanish (es)
Inventor
William J Dower
Michael C Needels
Ronald W Barrett
Alice V Bakker
Steven E Cwirla
Original Assignee
Medikine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medikine Inc filed Critical Medikine Inc
Publication of MX2022005404A publication Critical patent/MX2022005404A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022005404A 2019-11-05 2020-11-04 Compuestos de fijación a il-2r e il-7r dual. MX2022005404A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962930758P 2019-11-05 2019-11-05
US202062969432P 2020-02-03 2020-02-03
US202063041158P 2020-06-19 2020-06-19
US202063071946P 2020-08-28 2020-08-28
PCT/US2020/058969 WO2021092081A1 (en) 2019-11-05 2020-11-04 Dual il-2r and il-7r binding compounds

Publications (1)

Publication Number Publication Date
MX2022005404A true MX2022005404A (es) 2022-09-09

Family

ID=75686972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005404A MX2022005404A (es) 2019-11-05 2020-11-04 Compuestos de fijación a il-2r e il-7r dual.

Country Status (11)

Country Link
US (2) US11248030B2 (enExample)
EP (1) EP4055036A4 (enExample)
JP (2) JP7427287B2 (enExample)
KR (1) KR20220110209A (enExample)
AU (2) AU2020378282B2 (enExample)
BR (1) BR112022008750A2 (enExample)
CA (1) CA3160466A1 (enExample)
IL (1) IL292803A (enExample)
MX (1) MX2022005404A (enExample)
TW (1) TW202132330A (enExample)
WO (1) WO2021092081A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210055694A (ko) * 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
AU2021201047B2 (en) * 2018-08-06 2022-02-17 Medikine, Inc. Il-2 receptor binding compounds
CA3160466A1 (en) * 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
MX2022005411A (es) 2019-11-05 2022-08-10 Medikine Inc COMPUESTOS DE UNIÓN A IL-2RßYC.
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
EP4240394A4 (en) * 2020-11-04 2024-10-23 Medikine, Inc. IL-2R BETA-GAMMA C-BINDING COMPOUNDS AND USES THEREOF
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
US20240101959A1 (en) * 2022-09-06 2024-03-28 Medikine, Inc. Use of il-2r-beta-gamma agonist peptides in cell manufacturing
US20240100159A1 (en) * 2022-09-06 2024-03-28 Medikine, Inc. Use of il-7r-alpha-gamma agonist peptides in cell manufacturing

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ES2356154T3 (es) * 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
KR101163424B1 (ko) * 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Ｉｌ－７ 융합 단백질
US20120210458A9 (en) * 2009-02-27 2012-08-16 Yongwei Cao Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Thereof
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
EP2649094B1 (en) 2010-12-10 2016-04-27 University of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
CN102775496B (zh) * 2011-05-13 2014-10-08 中国医学科学院基础医学研究所 靶向清除hiv/siv的复合药物
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
US20190216898A1 (en) * 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN110177564A (zh) 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
KR20210055694A (ko) 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
MX2022005411A (es) 2019-11-05 2022-08-10 Medikine Inc COMPUESTOS DE UNIÓN A IL-2RßYC.
CA3160466A1 (en) * 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
AU2021217959A1 (en) 2020-02-03 2022-08-18 Medikine, Inc. IL-7Rα binding compounds
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds

Also Published As

Publication number Publication date
TW202132330A (zh) 2021-09-01
WO2021092081A1 (en) 2021-05-14
AU2023214299A1 (en) 2023-10-26
US11248030B2 (en) 2022-02-15
IL292803A (en) 2022-07-01
US20210130424A1 (en) 2021-05-06
JP7427287B2 (ja) 2024-02-05
AU2020378282A1 (en) 2022-06-09
CA3160466A1 (en) 2021-05-14
EP4055036A4 (en) 2024-02-28
JP2022553826A (ja) 2022-12-26
KR20220110209A (ko) 2022-08-05
US20220119465A1 (en) 2022-04-21
EP4055036A1 (en) 2022-09-14
JP2024056696A (ja) 2024-04-23
AU2020378282B2 (en) 2023-05-18
BR112022008750A2 (pt) 2022-07-19

Similar Documents

Publication Publication Date Title
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
MX2022004430A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
PH12021552538A1 (en) Heavy chain antibodies binding to psma
MX2022009302A (es) Compuestos de unión a il-7r¿.
EP4417263A3 (en) Cd3 binding antibodies
WO2020131586A3 (en) Methods for identifying neoantigens
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
PH12021551629A1 (en) Traceless linkers and protein-conjugates thereof
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MY209035A (en) Tricyclic compounds and their use
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MX2022007613A (es) Union de anticuerpos de cadena pesada a cd38.
MX2023005180A (es) Compuestos de union a il-2r\03b2?c y usos de estos.
MX337590B (es) Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
EP4585611A3 (en) Proteins binding nkg2d, cd16 and egfr
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
WO2018042385A3 (en) Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
AU2018278730A1 (en) A novel anti-c-Met antibody and use thereof
MX2024003993A (es) Proteinas que se unen al miembro d del grupo 2 de asesinos naturales (nkg2d), cumulo de diferenciacion 16(cd16) y receptor del factor activador de celulas b (baff-r).